DE60038675D1 - Rekombinantes plättchenkollagenrezeptorglykoprotein und dessen pharmazeutische verwendung - Google Patents

Rekombinantes plättchenkollagenrezeptorglykoprotein und dessen pharmazeutische verwendung

Info

Publication number
DE60038675D1
DE60038675D1 DE60038675T DE60038675T DE60038675D1 DE 60038675 D1 DE60038675 D1 DE 60038675D1 DE 60038675 T DE60038675 T DE 60038675T DE 60038675 T DE60038675 T DE 60038675T DE 60038675 D1 DE60038675 D1 DE 60038675D1
Authority
DE
Germany
Prior art keywords
pharmaceutical use
recombinant tissue
collagen receptor
tissue collagen
receptor glycoprotein
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE60038675T
Other languages
English (en)
Other versions
DE60038675T2 (de
Inventor
Kenneth J Clemetson
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sanofi Aventis Deutschland GmbH
Original Assignee
Sanofi Aventis Deutschland GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=8238132&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DE60038675(D1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Sanofi Aventis Deutschland GmbH filed Critical Sanofi Aventis Deutschland GmbH
Publication of DE60038675D1 publication Critical patent/DE60038675D1/de
Application granted granted Critical
Publication of DE60038675T2 publication Critical patent/DE60038675T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/745—Blood coagulation or fibrinolysis factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/745—Blood coagulation or fibrinolysis factors
    • C07K14/755—Factors VIII, e.g. factor VIII C (AHF), factor VIII Ag (VWF)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/86—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving blood coagulating time or factors, or their receptors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/54—F(ab')2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N15/00—Investigating characteristics of particles; Investigating permeability, pore-volume or surface-area of porous materials
    • G01N15/01—Investigating characteristics of particles; Investigating permeability, pore-volume or surface-area of porous materials specially adapted for biological cells, e.g. blood cells
    • G01N2015/018—Platelets
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
    • G01N2333/4701—Details
    • G01N2333/4728—Details alpha-Glycoproteins
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/78—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin, cold insoluble globulin [CIG]
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/02—Screening involving studying the effect of compounds C on the interaction between interacting molecules A and B (e.g. A = enzyme and B = substrate for A, or A = receptor and B = ligand for the receptor)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/22—Haematology
    • G01N2800/222—Platelet disorders

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Hematology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Urology & Nephrology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Food Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Wood Science & Technology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • General Engineering & Computer Science (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
DE60038675T 1999-05-07 2000-04-25 Rekombinantes plättchenkollagenrezeptorglykoprotein und dessen pharmazeutische verwendung Expired - Lifetime DE60038675T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP99109094 1999-05-07
EP99109094 1999-05-07
PCT/EP2000/003683 WO2000068377A1 (en) 1999-05-07 2000-04-25 Recombinant platelet collagen receptor glycoprotein vi and its pharmaceutical use

Publications (2)

Publication Number Publication Date
DE60038675D1 true DE60038675D1 (de) 2008-06-05
DE60038675T2 DE60038675T2 (de) 2009-07-02

Family

ID=8238132

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60038675T Expired - Lifetime DE60038675T2 (de) 1999-05-07 2000-04-25 Rekombinantes plättchenkollagenrezeptorglykoprotein und dessen pharmazeutische verwendung

Country Status (26)

Country Link
US (5) US7928066B1 (de)
EP (3) EP1942186B1 (de)
JP (2) JP5480457B2 (de)
KR (1) KR100703592B1 (de)
CN (1) CN1253569C (de)
AR (1) AR023848A1 (de)
AT (1) ATE393223T1 (de)
AU (1) AU775952B2 (de)
BR (1) BRPI0010325B1 (de)
CA (1) CA2372515C (de)
CY (2) CY1108190T1 (de)
CZ (1) CZ302693B6 (de)
DE (1) DE60038675T2 (de)
DK (2) DK1177289T3 (de)
ES (2) ES2534652T3 (de)
HK (1) HK1045714B (de)
HU (1) HUP0201049A2 (de)
MX (1) MXPA01011274A (de)
NO (1) NO333408B1 (de)
PL (1) PL204449B1 (de)
PT (2) PT2341141E (de)
RU (1) RU2287580C2 (de)
SI (1) SI1177289T1 (de)
SK (1) SK15762001A3 (de)
WO (1) WO2000068377A1 (de)
ZA (1) ZA200110071B (de)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SK15762001A3 (sk) 1999-05-07 2002-04-04 Merck Patent Gmbh Rekombinantný doštičkový kolagénový receptor glykoproteínu VI a jeho farmaceutické použitie
US7291714B1 (en) 1999-06-30 2007-11-06 Millennium Pharmaceuticals, Inc. Glycoprotein VI and uses thereof
US6245527B1 (en) 1999-06-30 2001-06-12 Millennium Pharmaceuticals, Inc. Nucleic acid molecules encoding glycoprotein VI and recombinant uses thereof
US20040001826A1 (en) 1999-06-30 2004-01-01 Millennium Pharmaceuticals, Inc. Glycoprotein VI and uses thereof
AU7097400A (en) * 1999-09-01 2001-03-26 Otsuka Pharmaceutical Co., Ltd. Platelet membrane glycoprotein vi (gpvi) dna and protein sequences, and uses thereof
EP1224942A1 (de) * 2001-01-23 2002-07-24 Bernhard Dr. Nieswandt Use of JAQ1 (monoclonal antibody anti GPVI) as a medicament for the protection against thrombotic diseases
EP1406929A2 (de) * 2001-07-18 2004-04-14 MERCK PATENT GmbH Glycoprotein vi fusionproteine
US7531178B2 (en) 2002-06-07 2009-05-12 Trigen Gmbh Immunoadhesin comprising a glycoprotein VI domain
EP1369128A1 (de) 2002-06-07 2003-12-10 Procorde GmbH Glycoprotein VI Inhibitoren und deren therapeutische Verwendung
US20070071744A1 (en) 2002-06-07 2007-03-29 Gotz Munch Agents which bind to epitopes of glycoprotein VI
DE102004017295A1 (de) * 2004-04-05 2005-11-03 Zlb Behring Gmbh Verbindungen, welche die Entfernung von Rezeptoren von Zelllmembranen bewirken oder verhindern, und Verfahren zu ihrem Nachweis
CN1964990B (zh) 2004-04-29 2012-12-12 大冢制药株式会社 糖蛋白ⅵ特异的抗体以及生产这些抗体的方法
US7645592B2 (en) 2004-04-29 2010-01-12 Otsuka Pharmaceutical Co., Ltd. Glycoprotein VI antibodies and methods of use thereof
WO2006117910A1 (ja) 2005-04-28 2006-11-09 Mochida Pharmaceutical Co., Ltd. 抗血小板膜糖蛋白質ⅵモノクローナル抗体
RU2010121878A (ru) * 2007-10-31 2011-12-10 Оцука Фармасьютикал Ко., Лтд. (Jp) Применения ингибитора гликопротеина vi (gpvi)
EP2694709B1 (de) 2011-04-08 2016-09-14 Prognosys Biosciences, Inc. Peptidkonstrukte und testsysteme dafür
EP3184544A1 (de) * 2015-12-23 2017-06-28 Julius-Maximilians-Universität Würzburg Glycoprotein-v-inhibitoren zur verwendung als koagulansien

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT662088E (pt) 1993-07-01 2002-06-28 Merck Patent Gmbh Inibidor da agregacao de plaquetas estimulada por colagenio
AU701576B2 (en) * 1993-10-22 1999-02-04 Trigen Limited Platelet-derived growth factor analogues
AU5927398A (en) * 1997-01-21 1998-08-07 Human Genome Sciences, Inc. Fc receptors and polypeptides
CA2250291A1 (en) * 1997-01-29 1998-07-30 Toray Industries Inc. Chimeric proteins, their heterodimer complexes, and platelet substitutes
SK15762001A3 (sk) 1999-05-07 2002-04-04 Merck Patent Gmbh Rekombinantný doštičkový kolagénový receptor glykoproteínu VI a jeho farmaceutické použitie
US7291714B1 (en) * 1999-06-30 2007-11-06 Millennium Pharmaceuticals, Inc. Glycoprotein VI and uses thereof
US20040001826A1 (en) 1999-06-30 2004-01-01 Millennium Pharmaceuticals, Inc. Glycoprotein VI and uses thereof
US6245527B1 (en) * 1999-06-30 2001-06-12 Millennium Pharmaceuticals, Inc. Nucleic acid molecules encoding glycoprotein VI and recombinant uses thereof
AU7097400A (en) * 1999-09-01 2001-03-26 Otsuka Pharmaceutical Co., Ltd. Platelet membrane glycoprotein vi (gpvi) dna and protein sequences, and uses thereof
EP1406929A2 (de) 2001-07-18 2004-04-14 MERCK PATENT GmbH Glycoprotein vi fusionproteine
EP1538165A1 (de) 2003-12-03 2005-06-08 Procorde GmbH Glycoprotein VI Inhibitoren auf der Basis des monoklonalen Antikörpers hgp 5c4

Also Published As

Publication number Publication date
NO333408B1 (no) 2013-05-27
AU4555500A (en) 2000-11-21
CZ20013989A3 (cs) 2002-02-13
CN1350583A (zh) 2002-05-22
JP5554696B2 (ja) 2014-07-23
KR20010112951A (ko) 2001-12-22
HK1045714A1 (en) 2002-12-06
EP1177289B1 (de) 2008-04-23
CY1116336T1 (el) 2017-02-08
JP2011097948A (ja) 2011-05-19
CA2372515C (en) 2015-12-01
PL204449B1 (pl) 2010-01-29
AR023848A1 (es) 2002-09-04
EP1942186A2 (de) 2008-07-09
DK1177289T3 (da) 2008-08-11
CZ302693B6 (cs) 2011-09-07
EP2341141B1 (de) 2015-01-14
PT1177289E (pt) 2008-06-30
US20160207976A1 (en) 2016-07-21
DK2341141T3 (en) 2015-04-20
KR100703592B1 (ko) 2007-04-05
EP1942186B1 (de) 2017-04-12
RU2287580C2 (ru) 2006-11-20
EP1177289A1 (de) 2002-02-06
HUP0201049A2 (hu) 2002-07-29
EP1942186A3 (de) 2008-10-08
NO20015420D0 (no) 2001-11-06
NO20015420L (no) 2002-01-03
ATE393223T1 (de) 2008-05-15
US7928066B1 (en) 2011-04-19
JP5480457B2 (ja) 2014-04-23
US20070172893A1 (en) 2007-07-26
DE60038675T2 (de) 2009-07-02
AU775952B2 (en) 2004-08-19
JP2003515313A (ja) 2003-05-07
MXPA01011274A (es) 2002-05-06
EP2341141A3 (de) 2012-03-28
SK15762001A3 (sk) 2002-04-04
WO2000068377A1 (en) 2000-11-16
US8198030B2 (en) 2012-06-12
EP2341141A2 (de) 2011-07-06
HK1045714B (zh) 2006-09-22
BRPI0010325B1 (pt) 2016-01-19
CY1108190T1 (el) 2014-02-12
SI1177289T1 (sl) 2008-08-31
US20070172480A1 (en) 2007-07-26
CN1253569C (zh) 2006-04-26
PT2341141E (pt) 2015-04-30
US20110237655A1 (en) 2011-09-29
US8278430B2 (en) 2012-10-02
PL351437A1 (en) 2003-04-22
ZA200110071B (en) 2003-03-06
ES2534652T3 (es) 2015-04-27
CA2372515A1 (en) 2000-11-16
ES2304347T3 (es) 2008-10-16
BR0010325A (pt) 2002-02-26

Similar Documents

Publication Publication Date Title
DE60038675D1 (de) Rekombinantes plättchenkollagenrezeptorglykoprotein und dessen pharmazeutische verwendung
NO993616D0 (no) Anlegg- og kronesystem for bruk med dentalimplantater
DE69836575D1 (de) Gewebestabilisierungsvorrichtung zur Verwendung in der Chirurgie
DE69820373D1 (de) Gewebestabilisierungsvorrichtung zur Verwendung in der Chirurgie
DE69816405D1 (de) Gewebestabilisierungsvorrichtung zur Verwendung in der Chirurgie
DE60032256D1 (de) Verbesserte sichtbarkeit medizinischer implantate
AU2003295614A8 (en) Delivery of pharmaceutical agents via the human insulin receptor
DE69929513D1 (de) Knochenprothese
CY2013032I1 (el) Συζυγη της εξενδινης-4 και η φαρμακευτικη τους χρηση
ATE231717T1 (de) Implantate mit phasenweiser arzneistoffabgabe
EE200100470A (et) Püridopüranoasepiini derivaadid, nende valmistamine ja terapeutiline kasutamine
PT1230230E (pt) Derivados de indeno-di-hidrotiazole sua preparacao e sua utilizacao como medicamentos anorexigenico
DE59906118D1 (de) Beschichtete medizinische geräte und implantate
FR2794019B1 (fr) Implant d'osteosynthese
ATE383868T1 (de) Pharmazeutische formulierung enthaltend megalatran und dessen pro-pharmaka
DE69928344D1 (de) Pharmazeutisches Implantat
DE60019389D1 (de) Chirurgischer Schwenkhaltering zur Verwendung in der Augenchirurgie
ATE252096T1 (de) Prolylendopeptidase-inhibitoren, ihre herstellung und ihre pharmazeutische verwendung
ATE251902T1 (de) Pharmazeutische zusammensetzung zur reduzierung der mcp-1 proteinsynthese
AU6929500A (en) Connective tissue growth factor receptor, its agonists and antagonists, and their therapeutic and diagnostic uses
DE69809928T2 (de) Tizoxanide und nitazoxanide enthaltende pharmazeutische zusammensetzungen
EE200000018A (et) 6-pürrolidiin-2-üülpüridiinid, nende valmistamine ja terapeutiline kasutamine
AU2003275948A8 (en) Pharmaceutical composition comprising a tissue factor antagonist and protein c polypeptides
DE69821227D1 (de) Verwendung von papovavirus kapsid-proteinen zur verabreichung therapeutischen agentien in nervzellen
DE60017741D1 (de) Medizinisches implantat

Legal Events

Date Code Title Description
8363 Opposition against the patent